These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38537950)

  • 1. "Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis." M. Kolb, B. Crestani and T.M. Maher.
    Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38537950
    [No Abstract]   [Full Text] [Related]  

  • 2. "Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis." Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler and Toby M. Maher. Eur Respir J 2016; 47: 1776-1784.
    Eur Respir J; 2016 Aug; 48(2):593. PubMed ID: 27478193
    [No Abstract]   [Full Text] [Related]  

  • 3. "Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis." Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58-64.
    Eur Respir Rev; 2015 Sep; 24(137):545. PubMed ID: 26324819
    [No Abstract]   [Full Text] [Related]  

  • 4. "Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis." Bridget F. Collins and Ganesh Raghu.
    Eur Respir Rev; 2019 Dec; 28(154):. PubMed ID: 31722893
    [No Abstract]   [Full Text] [Related]  

  • 5. "The therapy of idiopathic pulmonary fibrosis: what is next?" Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi,
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31554706
    [No Abstract]   [Full Text] [Related]  

  • 6. "Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis." Yasuhiro Kondoh, Vincent Cottin and Kevin K. Brown.
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29653947
    [No Abstract]   [Full Text] [Related]  

  • 7. "Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension." Irene M. Lang, Sean P. Gaine. Eur Respir Rev 2015; 24: 630-641.
    Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28049123
    [No Abstract]   [Full Text] [Related]  

  • 8. "Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension." Irene M. Lang and Sean P. Gaine. Eur Respir Rev 2015; 24: 630-641.
    Eur Respir Rev; 2016 Mar; 25(139):99. PubMed ID: 26929428
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression of Concern.
    Listed NA
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):445. PubMed ID: 38305629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms." S. Malenfant, M. Lebret, É. Breton-Gagnon,
    Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38355152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Malignant pleural effusion: from bench to bedside." Ioannis Psallidas, Ioannis Kalomenidis, Jose M. Porcel, Bruce W. Robinson and Georgios T. Stathopoulos. Eur Respir Rev 2016; 25: 189-198.
    Eur Respir Rev; 2016 Sep; 25(141):360. PubMed ID: 27581834
    [No Abstract]   [Full Text] [Related]  

  • 12. "Noninvasive respiratory support after extubation: a systematic review and network meta-analysis". A. Boscolo, T. Pettenuzzo, N. Sella, M. Zatta, M. Salvagno, M. Tassone, C. Pretto, A. Peralta, L. Muraro, F. Zarantonello, A. Bruni, F. Geraldini, A. De Cassai and P. Navalesi.
    Eur Respir Rev; 2023 Jun; 32(168):. PubMed ID: 37343963
    [No Abstract]   [Full Text] [Related]  

  • 13. "Cellular mechanisms underlying steroid-resistant asthma." Ridhima Wadhwa, Kamal Dua, Ian M. Adcock, Jay C. Horvat, Richard Y. Kim and Philip M. Hansbro.
    Eur Respir Rev; 2019 Dec; 28(154):. PubMed ID: 31722895
    [No Abstract]   [Full Text] [Related]  

  • 14. "Immune mechanisms in fibrotic pulmonary sarcoidosis". P. Weeratunga, D.R. Moller and L-P. Ho.
    Eur Respir Rev; 2023 Sep; 32(169):. PubMed ID: 37611949
    [No Abstract]   [Full Text] [Related]  

  • 15. "Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice." Stephen Y. Chan and Lewis J. Rubin.
    Eur Respir Rev; 2018 Mar; 27(147):. PubMed ID: 29367412
    [No Abstract]   [Full Text] [Related]  

  • 16. "Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD". Ariel A. Calderon, Colin Dimond, David F. Choy, Rajita Pappu, Michele A. Grimbaldeston, Divya Mohan and Kian Fan Chung.
    Eur Respir Rev; 2023 Jun; 32(168):. PubMed ID: 37019459
    [No Abstract]   [Full Text] [Related]  

  • 17. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis.
    Kolb M; Crestani B; Maher TM
    Eur Respir Rev; 2023 Mar; 32(167):. PubMed ID: 36813290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension." Irene Lang, Bernhard C. Meyer, Takeshi Ogo, Hiromi Matsubara, Marcin Kurzyna, Hossein-Ardeschir Ghofrani, Eckhard Mayer and Philippe Brenot.
    Eur Respir Rev; 2017 Jun; 26(144):. PubMed ID: 28615306
    [No Abstract]   [Full Text] [Related]  

  • 19. "Advanced medical interventions in pleural disease." Rahul Bhatnagar, John P. Corcoran, Fabien Maldonado, David Feller-Kopman, Julius Janssen, Philippe Astoul and Najib M. Rahman. Eur Respir Rev 2016; 25: 199-213.
    Eur Respir Rev; 2016 Sep; 25(141):360. PubMed ID: 27581835
    [No Abstract]   [Full Text] [Related]  

  • 20. Danger-associated molecular patterns and danger signals in idiopathic pulmonary fibrosis.
    Ellson CD; Dunmore R; Hogaboam CM; Sleeman MA; Murray LA
    Am J Respir Cell Mol Biol; 2014 Aug; 51(2):163-8. PubMed ID: 24749648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.